Welcome to our dedicated page for ICU Medical news (Ticker: ICUI), a resource for investors and traders seeking the latest updates and insights on ICU Medical stock.
ICU Medical Inc. (NASDAQ: ICUI) is dedicated to creating connections in healthcare. Headquartered in San Clemente, California, the company is a leader in designing and manufacturing some of the world's safest, most reliable medical devices and systems for infusion therapy, oncology, and critical care applications. ICU Medical’s extensive product line includes needle-free vascular access devices, custom infusion systems, closed delivery systems for hazardous drugs, advanced sensor catheters, and hemodynamic monitoring systems.
Founded on the principle of improving patient outcomes, ICU Medical's products help prevent bloodstream infections and protect both patients and healthcare workers from exposure to infectious diseases and hazardous drugs. The company has significantly expanded its market presence through strategic acquisitions, including Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022.
ICU Medical operates through three major segments: consumables, infusion systems, and vital care, contributing 43%, 28%, and 29% of consolidated revenue respectively. The company primarily serves the U.S. market, which accounts for over 63% of its sales. Their commitment to safety and quality ensures essential human and emotional connections between patients and caregivers, enhancing clinical experiences and overall quality of care.
Recent achievements underscore ICU Medical's robust financial performance. For the second quarter of 2023, the company reported revenues of $549.3 million with a GAAP gross profit of $192.3 million, marking a significant improvement in gross margin to 35% from the previous year’s 30%. Despite a GAAP net loss of $9.9 million, the adjusted diluted earnings per share were noted at $1.88, marking an increase from $1.37 year-over-year. The third-quarter results continued this positive trend with revenue reaching $553.3 million, though GAAP net income was recorded at $7.2 million.
For fiscal year 2023, ICU Medical has provided guidance, expecting GAAP net losses to range between $59 million and $38 million, alongside a forecasted adjusted EBITDA between $375 million and $405 million. The company's strategic focus remains on integrating acquisitions and enhancing operational efficiencies to drive future growth.
ICU Medical is not only a significant player in the medical device industry but also a beacon of innovation and quality, continually striving to meet the evolving needs of healthcare providers and patients globally.
ICU Medical (NASDAQ:ICUI) reported Q3 2024 financial results with revenue of $589.1 million, up from $553.3 million year-over-year. The company posted a GAAP net loss of $(33.0) million, or $(1.35) per diluted share, compared to a net income of $7.2 million, or $0.30 per share in Q3 2023. Gross margin improved to 34.8% from 33.2%. Adjusted EBITDA increased to $94.8 million from $89.8 million. The company updated its FY2024 guidance, projecting adjusted EBITDA of $355-365 million and adjusted EPS of $5.40-5.70.
ICU Medical and Otsuka Pharmaceutical Factory have announced a joint venture aimed at strengthening IV solutions manufacturing and innovation in North America. This partnership will create one of the largest global IV solutions manufacturing networks, producing an estimated 1.4 billion units annually. The joint venture will combine OPF's global manufacturing scale with ICU Medical's strong North American production and distribution capabilities, enhancing supply chain resiliency and accelerating new product development. ICU Medical will provide commercial services to ensure seamless operations. The venture is expected to become operational in early Q2 2025. Key economic terms include a $200 million upfront payment from OPF to ICU Medical, performance-based milestones by the end of 2026, and a put-call option in 2030 and beyond. This collaboration aims to address persistent supply chain challenges in the North American IV solutions market and deliver clinical and economic value to customers.
ICU Medical (ICUI) has announced its participation in the UBS Global Healthcare Conference in Rancho Palos Verdes, California, scheduled for November 11-14, 2024. The company's presentation is set for Wednesday, November 13, 2024, at 4:15 p.m. PT (7:15 p.m. ET). Management will also conduct one-on-one meetings on the same day. Investors and interested parties can access the live webcast through ICU Medical's website under the Investors and Event Calendar tabs, with replay options available.
ICU Medical (Nasdaq: ICUI) has scheduled its third quarter 2024 earnings release and conference call for Tuesday, November 12th, 2024. The company will release results at approximately 4:00 p.m. ET and host a conference call at 4:30 p.m. ET. Investors can access the call via phone at (800) 343-5172 using conference ID 'ICUMED' or through a webcast on the company's website. A replay of the webcast will be available afterward.
ICU Medical (Nasdaq:ICUI), a leading innovator in medical product development and manufacturing, has announced its participation in two major investor conferences this September. The company's CEO, Vivek Jain, will be attending:
1. The Wells Fargo 2024 Healthcare Conference in Boston on September 4, where he will engage in one-on-one meetings.
2. The Morgan Stanley 22nd Annual Global Healthcare Conference in New York on September 6, featuring a fireside chat at 4:00 a.m. PT (7:00 a.m. ET). This discussion will be webcast live on ICU Medical's Investor Relations website and archived for future viewing.
These events provide valuable opportunities for investors to gain insights into ICU Medical's operations and future plans.
ICU Medical (Nasdaq:ICUI) reported its Q2 2024 financial results. Revenue increased to $596.5 million, up from $549.3 million in Q2 2023. GAAP gross profit rose to $207.4 million, with a gross margin of 35%. However, the company reported a GAAP net loss of $(21.4) million, or $(0.88) per diluted share, compared to a loss of $(9.9) million in Q2 2023. Adjusted diluted EPS was $1.56, down from $1.88 in the previous year. Adjusted EBITDA decreased to $91.3 million from $98.1 million.
The company updated its fiscal year 2024 guidance, narrowing the range for adjusted EBITDA to $345-$365 million and increasing the range for diluted EPS to $4.95-$5.35. Revenue growth was observed across all product lines, with Consumables showing the largest increase.
ICU Medical (Nasdaq: ICUI), a leading innovator in medical product development and manufacturing, has announced its schedule for the second quarter 2024 earnings release and conference call. The company will disclose its Q2 2024 results on Wednesday, August 7th, 2024, at approximately 4:00 p.m. ET. Following this, a conference call will be held at 4:30 p.m. ET on the same day to discuss the results.
Interested parties can access the call by dialing (800) 579-2543 and using the conference ID "ICUMED". Additionally, a simultaneous webcast will be available on the company's website at www.icumed.com. To access the webcast, navigate to the Investors tab and click on the Webcast icon. The webcast will also be available for replay after the live event.
ICU Medical, Inc. announced its First Quarter 2024 Results with revenue of $566.7 million, a slight decrease from the previous year. The GAAP gross profit was $185.2 million, with a net loss of $(39.5) million. Adjusted diluted earnings per share were $0.96, and Adjusted EBITDA was $78.8 million. Revenues by product line showed fluctuations, with Vital Care including revenue from a Pfizer contract. CEO Vivek Jain stated that the results were as expected.
FAQ
What is the current stock price of ICU Medical (ICUI)?
What is the market cap of ICU Medical (ICUI)?
What does ICU Medical Inc. specialize in?
Where is ICU Medical Inc. headquartered?
What are the major segments of ICU Medical Inc.’s business?
What significant acquisitions has ICU Medical Inc. made?
How does ICU Medical Inc. contribute to patient safety?
What was ICU Medical Inc.’s revenue for the second quarter of 2023?
What is the geographic focus of ICU Medical Inc.’s sales?
What guidance has ICU Medical Inc. provided for fiscal year 2023?
What was ICU Medical Inc.’s adjusted diluted earnings per share for the second quarter of 2023?
How does ICU Medical Inc. foster human and emotional connections in healthcare?
